2851907-53-2
Chemical Structure
EBL-3599
- CAS No.: 2851907-53-2
- Formula:C29H37N9O5S2
- Molecular Weight:655.79
InChIKey: JHQIDWIWOVDFPG-UHFFFAOYSA-N
SMILES: N#CC1=CC(C)=NC(N2CCN(S(=O)(C3=CC=C(NC(C4=CC(CNCCCN)=CC=C4N(S(=O)(C)=O)C)=O)C=C3)=O)CC2)=N1
Biological Activity: EBL‑3599 is an LpxH inhibitor derived from JEDI‑852 and JEDI‑1444 (HY-187940). EBL-3599 exhibits antibacterial activity against E. coli, K. pneumoniae, and efflux-deficient A. baumannii, P. aeruginosa, and P. mirabilis. EBL-3599 exhibits dose-dependent in vivo efficacy against E. coli and K. pneumoniae in a mouse peritonitis model. EBL-3599 can be used for research on bacterial infections and peritonitis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
EBL-3599 | EBL‑3599 is an LpxH inhibitor derived from JEDI‑852 and JEDI‑1444 (HY-187940). EBL-3599 exhibits antibacterial activity against E. coli, K. pneumoniae, and efflux-deficient A. baumannii, P. aeruginosa, and P. mirabilis. EBL-3599 exhibits dose-dependent in vivo efficacy against E. coli and K. pneumoniae in a mouse peritonitis model. EBL-3599 can be used for research on bacterial infections and peritonitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dome PA, et al. From Obscurity to Opportunity: LpxH Emerges as a Promising Antibiotic Target in the Battle against Gram-Negative Pathogens. ACS infectious diseases. 2025 Nov 14;11(11):2993-3008.
- [2]. Ennis AF, et al. Design and Evaluation of Pyridinyl Sulfonyl Piperazine LpxH Inhibitors with Potent Antibiotic Activity Against Enterobacterales. JACS Au. 2024 Nov 25;4(11):4383-4393. [Content Brief]
- [3]. Huseby DL, et al. Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria. Proceedings of the National Academy of Sciences of the United States of America. 2024 Apr 09;121(15):e2317274121.
